SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (Nasdaq: SABS) is a clinical-stage biopharmaceutical company that entered the public markets through a de-SPAC merger with Big Rock Partners Acquisition Corp., a blank-check vehicle sponsored by Big Rock Partners. The company filed an 8-K on June 22, 2021, reflecting a key transactional milestone in the merger process. Operating in the biotechnology and biopharmaceutical sector, SAB Biotherapeutics focuses on developing human polyclonal antibody therapeutics produced through its proprietary genetically engineered cattle platform. The SPAC vehicle completed its IPO in 2020, with the business combination closing in late 2021. Sign up at SpacDesk for full filings, deal timelines, and analytics on SABS and the broader SPAC universe.